Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (41-50 of 154) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|June 20, 2020
Reconsidering the Trade-offs of Prostate Cancer ScreeningJonathan E Shoag, Yaw A Nyame, Roman Gulati, et al.
JAMA Oncology|March 25, 2016
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesJoshua A Roth, Roman Gulati, John L Gore, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 16, 2016
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and HarmsRoman Gulati, Heather H Cheng, Paul H Lange, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 1, 2023
Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?Lukas Owens, Kemal Caglar Gogebakan, Usha Menon, et al.
American Journal of Epidemiology|May 23, 2021
Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness StudyNathaniel Hendrix, Roman Gulati, Boshen Jiao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United StatesMegan Dann Fesinmeyer, Roman Gulati, Steve Zeliadt, et al.
Journal of the National Cancer Institute|November 9, 2023
Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologiesRuth Etzioni, Roman Gulati, Christos Patriotis, et al.
Plos One|February 15, 2019
A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry dataAndreas Karlsson, Alexandra Jauhiainen, Roman Gulati, et al.
Journal of the National Cancer Institute|February 16, 2013
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trialJing Xia, Roman Gulati, Margaret Au, et al.
Journal of the National Cancer Institute|March 5, 2025
Trends in Young-Onset Cancer Incidence: A Modeling PerspectiveLukas Owens, Allison Fung, Jonathan Shuhendler, et al.
Pageof 16

Showing results (41-50 of 154) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|June 20, 2020
Reconsidering the Trade-offs of Prostate Cancer ScreeningJonathan E Shoag, Yaw A Nyame, Roman Gulati, et al.
JAMA Oncology|March 25, 2016
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesJoshua A Roth, Roman Gulati, John L Gore, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 16, 2016
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and HarmsRoman Gulati, Heather H Cheng, Paul H Lange, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 1, 2023
Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?Lukas Owens, Kemal Caglar Gogebakan, Usha Menon, et al.
American Journal of Epidemiology|May 23, 2021
Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness StudyNathaniel Hendrix, Roman Gulati, Boshen Jiao, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United StatesMegan Dann Fesinmeyer, Roman Gulati, Steve Zeliadt, et al.
Journal of the National Cancer Institute|November 9, 2023
Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologiesRuth Etzioni, Roman Gulati, Christos Patriotis, et al.
Plos One|February 15, 2019
A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry dataAndreas Karlsson, Alexandra Jauhiainen, Roman Gulati, et al.
Journal of the National Cancer Institute|February 16, 2013
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trialJing Xia, Roman Gulati, Margaret Au, et al.
Journal of the National Cancer Institute|March 5, 2025
Trends in Young-Onset Cancer Incidence: A Modeling PerspectiveLukas Owens, Allison Fung, Jonathan Shuhendler, et al.
Pageof 16